title: Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
abstract: We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa treated patients with Parkinson's disease after first time intake of an irreversible monoamine oxidase-B inhibitor. One patient received 10 mg selegiline and eleven patients took 1 mg rasagiline. A significant decrease of monoamine oxidase-B activity appeared 2 and 4 h following monoamine oxidase-B inhibitor intake in comparison to baseline. We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing.
authors.affiliation: Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr 1, 13088, Berlin, Germany. th.mueller@alexianer.de.
authors.forename: Thomas
authors.initials: T
authors.lastname: Müller
authors.affiliation: Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Riederer
authors.affiliation: Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland.|Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zurich, Switzerland.|Zürich Center for Integrative Human Physiology, University of Zürich, Zurich, Switzerland.
authors.forename: Edna
authors.initials: E
authors.lastname: Grünblatt
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008995:Monoamine Oxidase / Q000097:blood*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology*; D012642:Selegiline / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D012642:Selegiline; D007980:Levodopa; D008995:Monoamine Oxidase
keywords: Monoamine oxidase; Rasagiline; Selegiline